Oncology Drugs Market - Forecast(2024 - 2030)

Report Code: HCR 1186 Report Format: PDF + Excel
1. Oncology Drugs Market - Overview
1.1. Definitions and Scope
2. Oncology Drugs Market - Executive summary
2.1. Market Revenue, Market Size and Key Trends by Company
2.2. Key Trends by type of Application
2.3. Key Trends segmented by Geography
3. Oncology Drugs Market 
3.1. Comparative analysis
3.1.1. Product Benchmarking - Top 10 companies
3.1.2. Top 5 Financials Analysis
3.1.3. Market Value split by Top 10 companies
3.1.4. Patent Analysis - Top 10 companies
3.1.5. Pricing Analysis 
4. Oncology Drugs Market – Startup companies Scenario Premium
4.1. Top 10 startup company Analysis by
4.1.1. Investment
4.1.2. Revenue
4.1.3. Market Shares
4.1.4. Market Size and Application Analysis
4.1.5. Venture Capital and Funding Scenario
5. Oncology Drugs Market – Industry Market Entry Scenario Premium
5.1. Regulatory Framework Overview
5.2. New Business and Ease of Doing business index
5.3. Case studies of successful ventures
5.4. Customer Analysis – Top 10 companies
6. Oncology Drugs Market Forces
6.1. Drivers
6.2. Constraints
6.3. Challenges
6.4. Porters five force model
6.4.1. Bargaining power of suppliers
6.4.2. Bargaining powers of customers
6.4.3. Threat of new entrants
6.4.4. Rivalry among existing players
6.4.5. Threat of substitutes 
7. Oncology Drugs Market -Strategic analysis
7.1. Value chain analysis
7.2. Opportunities analysis
7.3. Product life cycle
7.4. Suppliers and distributors Market Share
8. Oncology Drugs Market – By Therapy (Market Size -$Million / $Billion)
8.1. Market Size and Market Share Analysis 
8.2. Application Revenue and Trend Research
8.3. Product Segment Analysis
8.3.1. Introduction
8.3.2. Chemotherapy
8.3.3. Targeted Therapy
8.3.4. Immunotherapy (Biologics Therapy)
8.3.4.1. Monoclonal Antibodies 
8.3.4.2. Cancer Growth Inhibitors
8.3.4.3. Angiogenesis Inhibitors
8.3.4.4. Gene Therapy
8.3.4.5. Others
8.3.5. Hormonal Therapy
8.3.6. Others
9. Oncology Drugs Market – By Type of Cancer (Market Size -$Million / $Billion)
9.1. Introduction
9.2. Blood Cancer
9.2.1. Leukemia
9.2.2. Hodgkin Lymphoma (HL)
9.2.3. Non-Hodgkin Lymphoma (NHL)
9.2.4. Multiple Myeloma
9.3. Breast Cancer
9.3.1. In Situ Cancers
9.3.2. Invasive (Infiltrating) Breast Cancer
9.3.3. Others
9.4. Intestinal Cancer
9.4.1. Adenocarcinomas
9.4.2. Sarcoma
9.4.3. Gastrointestinal Stromal Tumors
9.4.4. Carcinoid
9.4.5. Others
9.5. Prostate Cancer
9.6. Respiratory/Lung cancer
9.6.1. Small Cell Lung Cancer
9.6.2. Non-Small Cell Lung Cancer
9.7. Cervical Cancer
9.7.1. Squamous Cell Carcinomas
9.7.2. Adenocarcinomas
9.7.3. Others
9.8. Skin Cancer
9.8.1. Melanoma
9.8.2. Non-Melanoma
9.9. Bone Cancer
9.9.1. Osteosarcoma
9.9.2.Chondrosarcoma
9.9.3.Chordoma
9.9.4.Ewing Tumor
9.9.5.Giant Cell Tumor of Bone
9.9.6.Fibrosarcoma and Malignant Fibrous Histiocytoma
9.9.7.Others
9.10. Colorectal Cancer
9.10.1. Adenocarcinomas
9.10.2. Carcinoids
9.10.3. Others
9.11. Kidney Cancer
9.11.1. Renal Cell Carcinoma
9.11.2. Urothelial Carcinoma
9.11.3. Sarcoma
9.11.4. Wilms Tumor
9.11.5. Others
9.12. Pancreatic Cancer
9.12.1. Exocrine Tumors
9.12.2. Endocrine Tumors
9.13. Ovarian Cancer
9.13.1. Epithelial Tumors
9.13.2. Germ Cell Carcinoma Tumors
9.13.3. Stromal Carcinoma Tumors
9.13.4. Others
9.14. Bladder Cancer
9.14.1. Urothelial Carcinoma
9.14.2. Squamous Cell Carcinoma
9.14.3. Adenocarcinoma
9.14.4. Others
9.15. Thyroid Cancer
9.15.1. Papillary Carcinoma
9.15.2. Follicular Carcinoma
9.15.3. Hurthle Cell Carcinoma
9.15.4. Medullary Thyroid Carcinoma
9.15.5. Anaplastic Carcinoma
9.16. Brain Cancer
9.17. Liver Cancer
9.17.1. Hepatocellular Carcinoma (HCC)
9.17.2. Fibrolamellar HCC
9.17.3. Cholangiocarcinoma
9.17.4. Angiosarcoma
9.17.5. Secondary Liver Cancer
9.18. Uterine Cancer
9.18.1. Endometrial Cancer
9.18.2. Uterine Sarcoma
9.19. Others
10. Oncology Drugs - By Geography (Market Size -$Million / $Billion)
10.1. Oncology Drugs Market - North America Segment Research
10.2. North America Market Research (Million / $Billion)
10.2.1. Segment type Size and Market Size Analysis 
10.2.2. Revenue and Trends
10.2.3. Application Revenue and Trends by type of Application
10.2.4. Company Revenue and Product Analysis
10.2.5. North America Product type and Application Market Size
10.2.5.1. U.S.
10.2.5.2. Canada 
10.2.5.3. Mexico 
10.2.5.4. Rest of North America
10.3. Oncology Drugs - South America Segment Research
10.4. South America Market Research (Market Size -$Million / $Billion)
10.4.1. Segment type Size and Market Size Analysis 
10.4.2. Revenue and Trends
10.4.3. Application Revenue and Trends by type of Application
10.4.4. Company Revenue and Product Analysis
10.4.5. South America Product type and Application Market Size
10.4.5.1. Brazil  
10.4.5.2. Venezuela
10.4.5.3. Argentina
10.4.5.4. Ecuador
10.4.5.5. Peru
10.4.5.6. Colombia 
10.4.5.7. Costa Rica
10.4.5.8. Rest of South America
10.5. Oncology Drugs - Europe Segment Research
10.6. Europe Market Research (Market Size -$Million / $Billion)
10.6.1. Segment type Size and Market Size Analysis 
10.6.2. Revenue and Trends
10.6.3. Application Revenue and Trends by type of Application
10.6.4. Company Revenue and Product Analysis
10.6.5. Europe Segment Product type and Application Market Size
10.6.5.1. U.K  
10.6.5.2. Germany 
10.6.5.3. Italy 
10.6.5.4. France
10.6.5.5. Netherlands
10.6.5.6. Belgium
10.6.5.7. Spain
10.6.5.8. Denmark
10.6.5.9. Rest of Europe
10.7. Oncology Drugs – APAC Segment Research
10.8. APAC Market Research (Market Size -$Million / $Billion)
10.8.1. Segment type Size and Market Size Analysis 
10.8.2. Revenue and Trends
10.8.3. Application Revenue and Trends by type of Application
10.8.4. Company Revenue and Product Analysis
10.8.5. APAC Segment – Product type and Application Market Size
10.8.5.1. China 
10.8.5.2. Australia
10.8.5.3. Japan 
10.8.5.4. South Korea
10.8.5.5. India
10.8.5.6. Taiwan
10.8.5.7. Malaysia
11. Oncology Drugs Market - Entropy
11.1. New product launches
11.2. M&A's, collaborations, JVs and partnerships
12. Oncology Drugs Market – Industry / Segment Competition landscape Premium
12.1. Market Share Analysis
12.1.1. Market Share by Country- Top companies
12.1.2. Market Share by Region- Top 10 companies
12.1.3. Market Share by type of Application – Top 10 companies
12.1.4. Market Share by type of Product / Product category- Top 10 companies
12.1.5. Market Share at global level- Top 10 companies
12.1.6. Best Practises for companies
13. Oncology Drugs Market – Key Company List by Country Premium
14. Oncology Drugs Market Company Analysis
14.1. Market Share, Company Revenue, Products, M&A, Developments
14.2. Company 1
14.3. Company 2
14.4. Company 3
14.5. Company 4
14.6. Company 5
14.7. Company 6
14.8. Company 7
14.9. Company 8
14.10. Company 9
14.11. Company 10 and More
"*Financials would be provided on a best efforts basis for private companies"
15. Oncology Drugs Market -Appendix
15.1. Abbreviations
15.2. Sources
16. Oncology Drugs Market -Methodology Premium
16.1. Research Methodology
16.1.1. Company Expert Interviews
16.1.2. Industry Databases
16.1.3. Associations
16.1.4. Company News
16.1.5. Company Annual Reports
16.1.6. Application Trends
16.1.7. New Products and Product database
16.1.8. Company Transcripts
16.1.9. R&D Trends
16.1.10. Key Opinion Leaders Interviews
16.1.11. Supply and Demand Trends